Turmeric compound tested as eye scanner for Alzheimer's
NCT ID NCT05774704
First seen Jan 20, 2026 · Last updated Jun 23, 2026 · Updated 23 times
Summary
This pilot study is testing whether taking curcumin (the active ingredient in turmeric) for two weeks can cross into the brain and attach to amyloid beta proteins, which are linked to Alzheimer's disease. Researchers will use eye imaging to detect these proteins and also check how curcumin affects the gut microbiome. The study involves 60 adults aged 40-89 who have amyloid deposits in their retina.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Tech University Health Sciences Center
RECRUITINGLubbock, Texas, 79430, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
curcumin
What this could lead to
If successful, this could point toward a way to detect or monitor Alzheimer's disease using a simple eye test.
What could go wrong
This is a very early, small pilot study (60 people) testing feasibility, not effectiveness. Curcumin is poorly absorbed, and results may not lead to any treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.